课题基金 / 基金详情

UTMB Clinical and Translational Science Award

UTMB Clinical and Translational Science Award
UTMB 临床和转化科学奖
批准号:
9270640
负责人:
David N. Herndon
金额:
$393.77万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-18 至 2020-03-31

项目摘要

项目成果

David N. Herndon的其他基金

相似基金

相关文献

中文摘要
翻译
德克萨斯大学医学分校(UTMB)的CTSA位于翻译研究所内 科学(ITS)是三个独立的UTMB研究所之一,成立于2007年。以其作为家庭的角色 临床和翻译研究,ITS为7名早期获得终身教职的教师提供初级任命- 职业翻译科学家。在过去的5年半里,我们改变了UTMB的研究文化,不断增长 从一个只重视以实验室为导向的个人研究的机构转变为一个拥抱 多学科翻译团队(MTT)解决重大健康问题的方法。我们有 开发了新的教育课程,在具有多种疾病的特殊人群中开展了重要的临床研究项目 现场临床试验(CT),并在德克萨斯州地区CTSA财团(TRCC)和 全国范围内。UTMB CTSA中心的使命是通过以下方式支持国家的卫生目标 通过以下方式生成、测试和传播综合团队科学、教育和最佳实践 利益相关者在所有阶段的参与。通过使用创新的持续改进模式进行管理 记分卡,UTMB CTSA将解决四个具体目标,以:1)在真正的 提高翻译研究所有阶段所需的技能。我们将团队环境作为一种 支持培训不同学习社区的教育框架。我们的创新, 企业家精神和团队领导力课程将被用于灌输专注的、适合职业阶段的 我们实习生的能力。我们在分享和传播创新教育内容方面发挥了带头作用 整个联盟的企业家精神和团队科学。2)。让所有阶段的利益相关者参与进来 翻译研究和CT。我们将扩大与利益相关者的实质性双向互动 来自社区、患者权益倡导团体、医疗保健提供者和我们的医疗系统,以评估健康 需要,设定CTSA的优先事项并传播能力。3)。整合所有类型的质量体系 翻译研究,包括特殊人群中的CT。我们已经为一个 通过临床研究办公室为高质量CT提供可持续支持的全大学计划, 在经验丰富的主任、可互操作的临床试验管理系统和员工的支持下,提供 简化了对CT启动、质量保证监测、研究管理和GCP所有阶段的支持 训练。4)。通过以四甲基偶氮唑盐为基础的创新促进转化性研究的开展。UTMB CTSA HUB在国家联合体中是独一无二的,它系统地应用了产学研混合体 模型,并开发了关于星云的形成、评估、影响和轨迹的证据基础 成功的MTT。我们将通过促进团队发展、领导力发展来激发MTT创新 通过一个独特的领导力发展学院,并将治疗和设备推进到I/II阶段 CTS在我们的“分子治疗和设备创新”可选模块中。
英文摘要
The CTSA at the University of Texas Medical Branch (UTMB) is located within the Institute for Translational Science (ITS), one of three free-standing UTMB institutes, established in 2007. In its role as the home for clinical and translational research, the ITS provides primary tenure-earning faculty appointments to 7 early- career translational scientists. Over the past 5½ years, we have transformed UTMB's research culture, growing from an institution that solely valued individual laboratory-oriented research to one that embraces multidisciplinary translational team (MTT) approaches to addressing significant health problems. We have developed novel educational curricula, significant clinical research programs in special populations with multi- site clinical trials (CTs), and provided leadership in the Texas Regional CTSA consortium (TRCC) and nationally. The mission of the UTMB CTSA hub is to support the health goals of the nation by generating, testing and disseminating integrative team science, education and best practices through stakeholder involvement at all stages. Managed by a continuous improvement model using an Innovation Scorecard, the UTMB CTSA will address four specific aims, to: 1) Train a diverse workforce in the authentic skills needed to advance all phases of translational research. We have used the team environment as an educational framework to support the training of diverse learning communities. Our innovation, entrepreneurship, and team leadership curricula will be used to instill focused, career stage-appropriate competencies in our trainees. We have led in sharing and disseminating innovative educational content in entrepreneurship and team science throughout the consortium. 2). Engage stakeholders across all phases of translational research and CTs. We will extend our substantial bidirectional interactions with stakeholders from the community, patient advocacy groups, healthcare providers and our Health System to assess health needs, set CTSA priorities and disseminate competencies. 3). Integrate quality systems through all types of translational research, including CTs in special populations. We have provided leadership to a university-wide plan for sustainable support for high-quality CTs through the Office of Clinical Research, supported by an experienced director, an interoperable Clinical Trial Management System and staff to provide streamlined support for all phases of CT start-up, quality assurance monitoring, study management and GCP training. 4). Advance the conduct of translational research through MTT-based innovation. The UTMB CTSA hub is unique in the national consortium in its systematic application of a hybrid industry-academic MTT model, and have developed an evidence base on the formation, evaluation, impact and trajectories of successful MTTs. We will stimulate MTT innovation by promoting team development, leadership development by a unique Leadership Development Academy, and advancement of therapeutics and devices into Phase I/II CTs in our “Innovations in Molecular Therapeutics and Devices” Optional Module.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ASSESSMENT OF ANABOLIC AGENTS AND EXERCISE IN BURNED CHILDREN
ASSESSMENT OF ANABOLIC AGENTS AND EXERCISE IN BURNED CHILDREN
ASSESSMENT OF ANABOLIC AGENTS AND EXERCISE IN BURNED CHILDREN
ASSESSMENT OF IMPROVED WOUND HEALING, RECOVERY AND REHABILITATION IN SEVERELY
海外基金